30 October 2026 announcement
WHO South-East Asia reported a collaboration with LEHS through its Wadhwani AI programme focused on responsible design, evaluation and use of artificial intelligence in India and the South-East Asia Region.
Why this matters in medicine
AI systems are increasingly considered for screening, decision support, documentation and health-system operations. Clinical usefulness must be demonstrated in the intended patient population and workflow rather than inferred from demonstrations or general-purpose benchmark scores.
Five evaluation questions
- Intended use: Is the system designed for triage, diagnosis support, administration or patient education?
- Clinical validity: Has performance been independently evaluated with representative data and meaningful outcomes?
- Safety: Are errors, subgroup differences, uncertainty and escalation paths monitored?
- Privacy: Are patient data collection, consent, retention and access controlled under applicable rules?
- Accountability: Can a qualified clinician review and override recommendations, and is there an audit trail?
Practical CHC considerations
Before deploying any AI workflow, define its scope, evaluate local language and population performance, protect identifiable patient information, train staff and establish incident reporting. Human clinical accountability remains essential.
What the announcement does not mean
The regional announcement is not regulatory clearance for a particular AI medical device, nor proof that any named product is safe or accurate.
Illustrative featured image: Irwan / Unsplash; not an image of the WHO collaboration.
Official source
WHO South-East Asia regional news listing, 30 October 2026.